{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:40:25Z","timestamp":1788867625545,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Katholisches Klinikum Bochum gGmbh"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Optic neuritis (ON) is a common manifestation of multiple sclerosis (MS) and myelin-oligodendrocyte-glycoprotein IgG-associated disease (MOGAD). This study evaluated the applicability of optical coherence tomography (OCT) for differentiating between both diseases in two independent cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred sixty two patients from seven sites underwent standard OCT and high-contrast visual acuity (HCVA) testing at least 6\u00a0months after first ON. Of these, 100 patients (32 MOGAD, 68 MS) comprised the primary investigational cohort, while 62 patients (31 MOGAD, 31 MS) formed a validation cohort. A composite score distinguishing between MOGAD and MS was developed using multivariate logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Bilateral simultaneous ON occurred more frequently in MOGAD compared to MS (46.9 vs. 11.8%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). OCT revealed more peripapillary retinal nerve fiber layer (pRNFL) atrophy in all segments in MOGAD\u00a0compared to predominantly temporal pRNFL atrophy in MS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). HCVA was better preserved in MS (<jats:italic>p<\/jats:italic>\u2009=\u20090.007). pRNFL thickness in all except for temporal segments was suitable for differentiating MOGAD and MS. Simultaneous bilateral ON and critical atrophy in nasal (&lt;\u200958.5\u00a0\u00b5m) and temporal superior (&lt;\u2009105.5\u00a0\u00b5m) segments were included into the composite score as three independent predictors for MOGAD. The composite score distinguished MOGAD from MS with 75% sensitivity and 90% specificity in the investigational cohort, and 68% sensitivity and 87% specificity in the validation cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Following a single ON-episode, MOGAD exhibits more pronounced global pRNFL atrophy and lower visual acuity after ON compared to MS. The introduced OCT-based composite score enabled differentiation between the two entities across both cohorts.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12666-w","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T13:02:41Z","timestamp":1725886961000},"page":"7222-7231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rapid differentiation of MOGAD and MS after a single optic neuritis"],"prefix":"10.1007","volume":"271","author":[{"given":"T.","family":"Pakeerathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Havla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schwake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-K.","family":"Pr\u00f6bstel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kulsvehagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Ayroza Galv\u00e3o Ribeiro Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cerd\u00e1-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. C.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Duchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Stellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Stolowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schneider-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-792X","authenticated-orcid":false,"given":"I.","family":"Ayzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"12666_CR1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1212\/CON.0000000000000768","volume":"25","author":"JL Bennett","year":"2019","unstructured":"Bennett JL (2019) Optic neuritis. Contin Lifelong Learn Neurol 25:1236\u20131264","journal-title":"Contin Lifelong Learn Neurol"},{"key":"12666_CR2","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266:1280\u20131286","journal-title":"J Neurol"},{"key":"12666_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22:268\u2013282","journal-title":"Lancet Neurol"},{"key":"12666_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms22010100","volume":"22","author":"W Ambrosius","year":"2020","unstructured":"Ambrosius W, Michalak S, Kozubski W et al (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci 22:100","journal-title":"Int J Mol Sci"},{"key":"12666_CR5","doi-asserted-by":"publisher","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ et al (2022) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 13:885218","journal-title":"Front Neurol"},{"key":"12666_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cei.13641","volume":"206","author":"F Bartels","year":"2021","unstructured":"Bartels F, Lu A, Oertel FC et al (2021) Clinical and neuroimaging findings in MOGAD\u2013MRI and OCT. Clin Exp Immunol 206:266\u2013281","journal-title":"Clin Exp Immunol"},{"key":"12666_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134","journal-title":"J Neuroinflammation"},{"key":"12666_CR8","doi-asserted-by":"publisher","first-page":"947630","DOI":"10.3389\/fneur.2022.947630","volume":"13","author":"GS Manzano","year":"2022","unstructured":"Manzano GS, Salky R, Mateen FJ et al (2022) Positive predictive value of MOG-IgG for clinically defined MOG-AD Within a Real-World Cohort. Front Neurol 13:947630","journal-title":"Front Neurol"},{"key":"12666_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","volume":"78","author":"E Sechi","year":"2021","unstructured":"Sechi E, Buciuc M, Pittock SJ et al (2021) Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 78:741\u2013746","journal-title":"JAMA Neurol"},{"key":"12666_CR10","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/NXI.0000000000001095","volume":"9","author":"YN Kwon","year":"2022","unstructured":"Kwon YN, Kim B, Kim J-S et al (2022) Myelin oligodendrocyte glycoprotein-Immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol - Neuroimmunol Neuroinflammation 9:e1095","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"12666_CR11","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","volume":"100","author":"S Carta","year":"2023","unstructured":"Carta S, Cobo Calvo \u00c1, Armangu\u00e9 T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100:e1095\u2013e1108","journal-title":"Neurology"},{"key":"12666_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2023.2523","volume":"80","author":"ABAGR Gomes","year":"2023","unstructured":"Gomes ABAGR, Kulsvehagen L, Lipps P et al (2023) Immunoglobulin a antibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with central nervous system demyelination. JAMA Neurol 80:989","journal-title":"JAMA Neurol"},{"key":"12666_CR13","doi-asserted-by":"publisher","first-page":"103525","DOI":"10.1016\/j.msard.2022.103525","volume":"58","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Sotirchos ES, Henderson AD et al (2022) OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. Mult Scler Relat Disord 58:103525","journal-title":"Mult Scler Relat Disord"},{"key":"12666_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00415-020-10097-x","volume":"268","author":"R Vicini","year":"2021","unstructured":"Vicini R, Br\u00fcgger D, Abegg M et al (2021) Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis. J Neurol 268:276\u2013284","journal-title":"J Neurol"},{"key":"12666_CR15","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1007\/s00415-022-11256-y","volume":"269","author":"T Pakeerathan","year":"2022","unstructured":"Pakeerathan T, Havla J, Schwake C et al (2022) Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode. J Neurol 269:6366\u20136376","journal-title":"J Neurol"},{"key":"12666_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"key":"12666_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltr\u00e1n E et al (2018) Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 84:315\u2013328","journal-title":"Ann Neurol"},{"key":"12666_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.0000000000012125","volume":"97","author":"A Aytulun","year":"2021","unstructured":"Aytulun A, Cruz-Herranz A, Aktas O et al (2021) APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology 97:68\u201379","journal-title":"Neurology"},{"key":"12666_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1352458514538110","volume":"21","author":"S Schippling","year":"2015","unstructured":"Schippling S, Balk LJ, Costello F et al (2015) Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler Houndmills Basingstoke Engl 21:163\u2013170","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"12666_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E Von Elm","year":"2008","unstructured":"Von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344\u2013349","journal-title":"J Clin Epidemiol"},{"key":"12666_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","volume":"7","author":"MA Lana-Peixoto","year":"2019","unstructured":"Lana-Peixoto MA, Talim N (2019) Neuromyelitis optica spectrum disorder and Anti-MOG syndromes. Biomedicines 7:42","journal-title":"Biomedicines"},{"key":"12666_CR22","first-page":"205521731879119","volume":"4","author":"J Srikajon","year":"2018","unstructured":"Srikajon J, Siritho S, Ngamsombat C et al (2018) Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. Mult Scler J Exp Transl Clin 4:205521731879119","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12666_CR23","doi-asserted-by":"publisher","first-page":"103222","DOI":"10.1016\/j.msard.2021.103222","volume":"56","author":"T Akaishi","year":"2021","unstructured":"Akaishi T, Himori N, Takeshita T et al (2021) Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. Mult Scler Relat Disord 56:103222","journal-title":"Mult Scler Relat Disord"},{"key":"12666_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","volume":"264","author":"J Havla","year":"2017","unstructured":"Havla J, K\u00fcmpfel T, Schinner R et al (2017) Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 264:139\u2013151","journal-title":"J Neurol"},{"key":"12666_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12974-021-02160-9","volume":"18","author":"J Havla","year":"2021","unstructured":"Havla J, Pakeerathan T, Schwake C et al (2021) Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation 18:121","journal-title":"J Neuroinflammation"},{"key":"12666_CR26","first-page":"205521731878782","volume":"4","author":"L Pandit","year":"2018","unstructured":"Pandit L, Mustafa S, Nakashima I et al (2018) MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. Mult Scler J Exp Transl Clin 4:2055217318787829","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12666_CR27","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1212\/NXI.0000000000000665","volume":"7","author":"M Pawlitzki","year":"2020","unstructured":"Pawlitzki M, Horbr\u00fcgger M, Loewe K et al (2020) MS optic neuritis-induced long-term structural changes within the visual pathway. Neurol Neuroimmunol Neuroinflammation 7:e665","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"12666_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","volume":"400","author":"H Song","year":"2019","unstructured":"Song H, Zhou H, Yang M et al (2019) Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China. J Neurol Sci 400:83\u201389","journal-title":"J Neurol Sci"},{"key":"12666_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ophtha.2005.10.040","volume":"113","author":"JB Fisher","year":"2006","unstructured":"Fisher JB, Jacobs DA, Markowitz CE et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113:324\u2013332","journal-title":"Ophthalmology"},{"key":"12666_CR30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","volume":"21","author":"J Bennett","year":"2015","unstructured":"Bennett J, de Seze J, Lana-Peixoto M et al (2015) Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler J 21:678\u2013688","journal-title":"Mult Scler J"},{"key":"12666_CR31","first-page":"205521732110631","volume":"7","author":"S Barnes","year":"2021","unstructured":"Barnes S, You Y, Shen T et al (2021) Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. Mult Scler J Exp Transl Clin 7:20552173211063130","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12666_CR32","doi-asserted-by":"publisher","first-page":"204062231988220","DOI":"10.1177\/2040622319882205","volume":"10","author":"TE Yap","year":"2019","unstructured":"Yap TE, Balendra SI, Almonte MT et al (2019) Retinal correlates of neurological disorders. Ther Adv Chronic Dis 10:2040622319882205","journal-title":"Ther Adv Chronic Dis"},{"key":"12666_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2017.00710","volume":"8","author":"C La Morgia","year":"2017","unstructured":"La Morgia C, Di Vito L, Carelli V et al (2017) Patterns of retinal ganglion cell damage in neurodegenerative disorders: parvocellular vs. magnocellular degeneration in optical coherence tomography studies. Front Neurol 8:710","journal-title":"Front Neurol"},{"key":"12666_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12974-019-1521-5","volume":"16","author":"FC Oertel","year":"2019","unstructured":"Oertel FC, Outteryck O, Knier B et al (2019) Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflammation 16:154","journal-title":"J Neuroinflammation"},{"key":"12666_CR35","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","volume":"26","author":"S Salama","year":"2020","unstructured":"Salama S, Khan M, Shanechi A et al (2020) MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler Houndmills Basingstoke Engl 26:1854\u20131865","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"12666_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ana.26440","volume":"92","author":"FC Oertel","year":"2022","unstructured":"Oertel FC, Sotirchos ES, Zimmermann HG et al (2022) Longitudinal retinal changes in MOGAD. Ann Neurol 92:476\u2013485","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12666-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T09:05:33Z","timestamp":1731488733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12666-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["12666"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12666-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Pakeerathan has no conflicts of interest related to this study. J. Havla reports grants from the Friedrich-Baur-Stiftung, Merck and Horizon, personal fees and non-financial support from Alexion, Horizon, Roche, Merck, Novartis, Biogen, BMS, Hexal and Janssen, and non-financial support from the Guthy-Jackson Charitable Foundation and The Sumaira Foundation. C. Schwake has no conflicts of interest. A. Salmen received speaker honoraria for activities with Bristol Myers Squibb, CSL Behring, Novartis, and Roche, and research support by the Baasch Medicus Foundation, the Medical Faculty of the University of Bern and the Swiss MS Society. M. Ringelstein received speaker honoraria from Novartis, Bayer Vital GmbH, Roche, Alexion, Horizon and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Roche, Horizon, Alexion and Merck, none related to this study. O. Aktas reports grants from the German Ministry of Education and Research (BMBF) and the German Research Foundation (DFG); grants and personal fees from Biogen and Novartis; and travel support and personal fees from Alexion, Almirall, MedImmune, Merck Serono, Roche, Sanofi, Viela Bio\/Horizon Therapeutics and Zambon. M. Weise has no conflicts of interest. JA. Gernert reports travel expenses and non-financial support from Merck, outside the submitted work, and received a research grant from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB\/TRR 274, ID 408885537). B. Kornek received speaker honoraria from Bayer, Biogen, Celgene-BMS, Merck, Novartis, Roche, Sanofi Genzyme, and Teva and participated in advisory boards from Celgene-BMS, Merck, Novartis, Sanofi Genzyme, and Roche. No COIs related to this study. G. Bsteh has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Janssen, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene\/BMS, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. He has received financial support in the past 12\u00a0months by unrestricted research grants (Celgene\/BMS, Novartis). No COIs related to this study. A-K. Pr\u00f6bstel received speaker and\/or consultation honoraria or travel funding from Roche, Merck, Novartis not related to this work. A. Papadopoulou received speaker-fees\/fees for advisory boards from Sanofi-Genzyme, Eli Lilly, AbbVie, Lundbeck and TEVA and travel support from Bayer AG, Teva and Hoffmann-La Roche. Her research was supported by the University- and University Hospital of Basel, the Swiss Multiple Sclerosis Society, the \u201cStiftung zur F\u00f6rderung der gastroenterologischen und allgemeinen klinischen Forschung sowie\u2028der medizinischen Bildauswertung\u201d, the \u201cFreie Akademische Gesellschaft Basel\u201d and the Swiss National Science Foundation (Project number: P300PB_174480). L. Kulsvehagen has no conflicts of interest. AB. Ayroza Galv\u00e3o Ribeiro Gomes has received a research grant from Roche, and travel grants from Roche and Biogen. She was a recipient of an ECTRIMS Clinical Fellowship and a Swiss Government Excellence Scholarship in 2020. N. Cerd\u00e1 Fuertes has no conflicts of interest. F. Oertel received fellowship support by the National Multiple Sclerosis Society (US), American Academy of Neurology, Hertie foundation for excellence in clinical neuroscience and the Deutsche Gesellschaft f\u00fcr Neurologie \u2013 all unrelated to this project. AS. Duchow has no conflicts of interest related to this study. F. Paul has received honoraria and research support from Alexion, Bayer, Biogen, Chugai, MerckSerono, Novartis, Genyzme, MedImmune, Shire, and Teva Pharmaceuticals, and serves on scientific advisory boards for Alexion, MedImmune, Novartis, and UCB. He has received funding from Deutsche Forschungsgemeinschaft (DFG Exc 257), Bundesministerium f\u00fcr Bildung und Forschung (Competence Network Multiple Sclerosis), Guthy-Jackson Charitable Foundation, EU Framework Program 7, and National Multiple Sclerosis Society of the USA. He serves on the steering committee of the N-Momentum study with inebilizumab (Horizon Therapeutics) and the OCTiMS Study (Novartis). He is an associatee editor with Neurology, Neuroimmunology, and Neuroinflammation and academic editor with PloS One. JP. Stellmann has no conflicts of interest related to this study. N. Stolowy has no conflicts of interest. K. Hellwig received speaker's, board honoraria, and research support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva. Her department received grant support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva. C. Schneider-Gold has received public speaking honoraria and\/or compensation for advisory boards\/consultation fees from Alexion Pharmaceuticals, Amicus Therapeutics, argenx, Bayer Schering, Hormosan Pharma, Immunovant, Janssen, Lupin Pharmaceuticals, Roche Pharma, Teva Pharmaceuticals, and UCB. All not related to the content of this study. T. K\u00fcmpfel has received received speaker honoraria and\/or personal fees for advisory boards from Novartis Pharma, Roche Pharma, Alexion\/Astra Zeneca, Horizon, Merck, Chugai and Biogen. The Institution she works for has received grant support for her research from Bayer-Schering AG, Novartis and Chugai Pharma in the past. All not related to the content of this study. R. Gold received speaker\u2019s and board honoraria from Baxter, Bayer Schering, Biogen Idec, CLB Behring, Genzyme, Merck Serono, Novartis, Stendhal, Talecris, and Teva. His department received grant support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva. All not related to the content of this study. P. Albrecht received research grants, speaker honoraria and travel grants and served on scientific advisory boards from Allergan\/Abbvie, Celgene\/BMS, Biogen, Merz, Janssen, Merck, Novartis, Roche, and received speaker honoraria from Bayer Schering, Hexal, Lilly, Sanofi, TEVA, none related to this study. I. Ayzenberg has received travel grants from Alexion, BMS, Biogen Idec and Guthy-Jackson Charitable Foundation, served on scientific advisory boards for Merck, Roche, Alexion, Horizon, Sanofi and received research support from Diamed, none related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Written informed consent was obtained from all patients and their legal representatives participating in the study. The local ethics committees approved the study protocol in accordance with the Declaration of Helsinki (1964) in its currently applicable version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}